Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2020

open access

Vol 56, No 5 (2005)
Original paper
Published online: 2006-05-28
Submitted: 2013-02-15
View PDF (polish) Download PDF file
Get Citation

Clinical course and treatment of patients with differentiated

Agnieszka Czarniecka, Jan Włoch, Michał Jarząb, Jolanta Krajewska, Aleksandra Kukulska, Józef Roskosz, Zbigniew Puch, Aleksandra. Wróbel, Magdalena Wollak, Maria Turska, Zoran Stojcev, Bogusław Mąka
Endokrynologia Polska 2005;56(5):758-765.

open access

Vol 56, No 5 (2005)
Original Paper
Published online: 2006-05-28
Submitted: 2013-02-15

Abstract

The aim of the study was to analyze the clinical course and therapy in patients with differentiated thyroid carcinoma (DTC) diagnosed in Poland within the year 1995. The group of 478 patients with thyroid cancer (57.7% of all thyroid cancer cases diagnosed this year in Poland) was analyzed. Patients were diagnosed or treated in Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Detailed analysis was performed in 352 patients with DTC who were treated by surgery. 292 patients (60%) received adjuvant radioiodine therapy. Hormonal (L-thyroxine) treatment was administered to all patients. In 37 patients (8.6%) local recurrence was observed. 10-year overall survival was 96.4% and disease-free survival was respectively 68%. The comparison of Polish data to analysis in German population published by Holtzer et al. (Cancer, 2000) was also performed in this study. We conclude that DTC therapy, currently recommended in our country, gives satisfactory results and that clinical outcome and therapeutic methods are similar both in Poland and Germany.

Abstract

The aim of the study was to analyze the clinical course and therapy in patients with differentiated thyroid carcinoma (DTC) diagnosed in Poland within the year 1995. The group of 478 patients with thyroid cancer (57.7% of all thyroid cancer cases diagnosed this year in Poland) was analyzed. Patients were diagnosed or treated in Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Detailed analysis was performed in 352 patients with DTC who were treated by surgery. 292 patients (60%) received adjuvant radioiodine therapy. Hormonal (L-thyroxine) treatment was administered to all patients. In 37 patients (8.6%) local recurrence was observed. 10-year overall survival was 96.4% and disease-free survival was respectively 68%. The comparison of Polish data to analysis in German population published by Holtzer et al. (Cancer, 2000) was also performed in this study. We conclude that DTC therapy, currently recommended in our country, gives satisfactory results and that clinical outcome and therapeutic methods are similar both in Poland and Germany.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

differentiated thyroid cancer; combined therapy

About this article
Title

Clinical course and treatment of patients with differentiated

Journal

Endokrynologia Polska

Issue

Vol 56, No 5 (2005)

Article type

Original paper

Pages

758-765

Published online

2006-05-28

Bibliographic record

Endokrynologia Polska 2005;56(5):758-765.

Keywords

differentiated thyroid cancer
combined therapy

Authors

Agnieszka Czarniecka
Jan Włoch
Michał Jarząb
Jolanta Krajewska
Aleksandra Kukulska
Józef Roskosz
Zbigniew Puch
Aleksandra. Wróbel
Magdalena Wollak
Maria Turska
Zoran Stojcev
Bogusław Mąka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl